{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:33:04Z","timestamp":1792427584518,"version":"4.5.0"},"reference-count":50,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1248\/bpb.b13-00743","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T23:04:17Z","timestamp":1386025457000},"page":"274-285","source":"Crossref","is-referenced-by-count":40,"title":["Therapeutic Effects of Multifunctional Tetramethylpyrazine Nitrone on Models of Parkinson\u2019s Disease <i>in Vitro<\/i> and <i>in Vivo<\/i>"],"prefix":"10.1248","volume":"37","author":[{"given":"Baojian","family":"Guo","sequence":"first","affiliation":[{"name":"Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daping","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Duan","sequence":"additional","affiliation":[{"name":"Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[{"name":"Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon MingYuen","family":"Lee","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novere N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G: Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Disco.<\/i>, 5<\/b>, 845–854 (2006)."},{"key":"2","unstructured":"2) Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I: Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neuro.<\/i>, 8<\/b>, 1150–1157 (2009)."},{"key":"3","unstructured":"3) Lees AJ, Hardy J, Revesz T: Parkinson's disease. Lance.<\/i>, 373<\/b>, 2055–2066 (2009)."},{"key":"4","unstructured":"4) Song L, Song W, Schipper HM: Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury. J Neurosci Re.<\/i>, 85<\/b>, 2186–2195 (2007)."},{"key":"5","unstructured":"5) Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S: 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Che.<\/i>, 281<\/b>, 5373–5382 (2006)."},{"key":"6","unstructured":"6) Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, Silverman RB: CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commu.<\/i>, 3<\/b>, 1146 (2012)."},{"key":"7","unstructured":"7) Barnham KJ, Masters CL, Bush AI: Neurodegenerative diseases and oxidative stress. Nat Rev Drug Disco.<\/i>, 3<\/b>, 205–214 (2004)."},{"key":"8","unstructured":"8) Hirsch EC, Hunot S, Hartmann A: Neuroinflammatory processes in Parkinson's disease. Parkinsonism & related disorder.<\/i>, 11 Suppl 1<\/b>, S9-S15 (2005)."},{"key":"9","unstructured":"9) Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T, Kameda M, Uozumi T, Tajiri N, Morimoto T, Jing M, Baba T, Wang F, Leung H, Matsui T, Miyoshi Y, Date I: Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosc.<\/i>, 9<\/b>, 75 (2008)."},{"key":"10","unstructured":"10) Zhang ZJ, Cheang LC, Wang MW, Lee SM: Quercetin exerts a neuroprotective effect through inhibition of the iNOS\/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. Int J Mol Me.<\/i>, 27<\/b>, 195–203 (2011)."},{"key":"11","unstructured":"11) Youdim MB, Geldenhuys WJ, Van der Schyf CJ: Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat Disor.<\/i>, 13 Suppl 3<\/b>, S281–291 (2007)."},{"key":"12","unstructured":"12) Tan Z: Neural protection by naturopathic compounds-an example of tetramethylpyrazine from retina to brain. J Ocul Biol Dis Info.<\/i>, 2<\/b>, 57–64 (2009)."},{"key":"13","unstructured":"13) Hu JZ, Huang JH, Xiao ZM, Li JH, Li XM, Lu HB: Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation. J Neurol Sc.<\/i>, 324<\/b>, 94–99 (2013)."},{"key":"14","unstructured":"14) Kao TK, Chang CY, Ou YC, Chen WY, Kuan YH, Pan HC, Liao SL, Li GZ, Chen CJ: Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp Neuro.<\/i>, 247C<\/b>, 188–201 (2013)."},{"key":"15","unstructured":"15) Ren Z, Ma J, Zhang P, Luo A, Zhang S, Kong L, Qian C: The effect of ligustrazine on L-type calcium current, calcium transient and contractility in rabbit ventricular myocytes. J Ethnopharmaco.<\/i>, 144<\/b>, 555–561 (2012)."},{"key":"16","unstructured":"16) Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W: Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sc.<\/i>, 72<\/b>, 2465–2472 (2003)."},{"key":"17","unstructured":"17) Shih YH, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS: Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. Neurorepor.<\/i>, 13<\/b>, 515–519 (2002)."},{"key":"18","unstructured":"18) Chang Y, Hsiao G, Chen SH, Chen YC, Lin JH, Lin KH, Chou DS, Sheu JR: Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol Si.<\/i>, 28<\/b>, 327–333 (2007)."},{"key":"19","unstructured":"19) Liao SL, Kao TK, Chen WY, Lin YS, Chen SY, Raung SL, Wu CW, Lu HC, Chen CJ: Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci Let.<\/i>, 372<\/b>, 40–45 (2004)."},{"key":"20","unstructured":"20) Zhang C, Wang SZ, Zuo PP, Cui X, Cai J: Protective effect of tetramethylpyrazine on learning and memory function in D-galactose-lesioned mice. Chin Med Sci .<\/i>, 19<\/b>, 180–184 (2004)."},{"key":"21","unstructured":"21) Wang DQ, Wang W, Jing FC: [Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson's disease]. Zhongguo Zhong Xi Yi Jie He Za Zh.<\/i>, 27<\/b>, 629–632 (2007)."},{"key":"22","unstructured":"22) Floyd RA, Castro Faria Neto HC, Zimmerman GA, Hensley K, Towner RA: Nitrone-based therapeutics for neurodegenerative diseases: Their use alone or in combination with lanthionines. Free Radic Biol Me.<\/i>, 62<\/b>, 145–156 (2013)."},{"key":"23","unstructured":"23) Saito K, Kobayashi C, Ikeda M: Effect of radical scavenger N-tert-butyl-alpha-phenylnitrone on stroke in a rat model using a telemetric system. J Pharm Pharm Sc.<\/i>, 11<\/b>, 25–31 (2008)."},{"key":"24","unstructured":"24) Yang J, Ahn HN, Chang M, Narasimhan P, Chan PH, Song YS: Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J Neuroche.<\/i>, 124<\/b>, 523–535 (2013)."},{"key":"25","unstructured":"25) Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U: NXY-059 for the treatment of acute ischemic stroke. N Engl J Me.<\/i>, 357<\/b>, 562–571 (2007)."},{"key":"26","unstructured":"26) Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, Liu W, Wang Y: Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg Med Che.<\/i>, 16<\/b>, 8868–8874 (2008)."},{"key":"27","unstructured":"27) Sun Y, Yu P, Zhang G, Wang L, Zhong H, Zhai Z, Wang Y: Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models. J Neurosci Re.<\/i>, 90<\/b>, 1662–1669 (2012)."},{"key":"28","unstructured":"28) Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, Tian Z, Wright SC, Larrick JW, Wang Y: Synthesis and evaluation of antibacterial activities of andrographolide analogues. European journal of medicinal chemistr.<\/i>, 44<\/b>, 2936–2943 (2009)."},{"key":"29","unstructured":"29) Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD: PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB .<\/i>, 22<\/b>, 2488–2497 (2008)."},{"key":"30","unstructured":"30) Hung MW, Zhang ZJ, Li S, Lei B, Yuan S, Cui GZ, Man Hoi P, Chan K, Lee SM: From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound. Evid Based Complement Alternat Me.<\/i>, 2012<\/b>, 605303 (2012)."},{"key":"31","unstructured":"31) Cui W, Zhang Z, Li W, Hu S, Mak S, Zhang H, Han R, Yuan S, Li S, Sa F, Xu D, Lin Z, Zuo Z, Rong J, Ma ED, Choi TC, Lee SM, Han Y: The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br J Pharmaco.<\/i>, 168<\/b>, 1201–1214 (2013)."},{"key":"32","unstructured":"32) Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S: Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neuroche.<\/i>, 78<\/b>, 1073–1082 (2001)."},{"key":"33","unstructured":"33) Zhao Q, Gao J, Li W, Cai D: Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease. Brain Re.<\/i>, 1346<\/b>, 224–236 (2010)."},{"key":"34","unstructured":"34) Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Proto.<\/i>, 2<\/b>, 141–151 (2007)."},{"key":"35","unstructured":"35) Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS: Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosc.<\/i>, 24<\/b>, 2045–2053 (2004)."},{"key":"36","unstructured":"36) He XJ, Yamauchi H, Uetsuka K, Nakayama H: Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease. Neurotoxicolog.<\/i>, 29<\/b>, 413–420 (2008)."},{"key":"37","unstructured":"37) Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T: Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Trans.<\/i>, 115<\/b>, 831–842 (2008)."},{"key":"38","unstructured":"38) Zhang Z, Cui W, Li G, Yuan S, Xu D, Hoi MP, Lin Z, Dou J, Han Y, Lee SM: Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1\/Nrf2\/HO-1 and involving PKCalpha and PI3K\/AKT signaling pathways. J Agric Food Che.<\/i>, 60<\/b>, 8171–8182 (2012)."},{"key":"39","unstructured":"39) Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ: 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Natur.<\/i>, 447<\/b>, 1081–1086 (2007)."},{"key":"40","unstructured":"40) Iancu R, Mohapel P, Brundin P, Paul G: Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Re.<\/i>, 162<\/b>, 1–10 (2005)."},{"key":"41","unstructured":"41) Endoh H, Kato N, Fujii S, Suzuki Y, Sato S, Kayama T, Kotake Y, Yoshimura T: Spin trapping agent, phenyl N-tert-butylnitrone, reduces nitric oxide production in the rat brain during experimental meningitis. Free Radic Re.<\/i>, 35<\/b>, 583–591 (2001)."},{"key":"42","unstructured":"42) Durand G, Choteau F, Pucci B, Villamena FA: Reactivity of superoxide radical anion and hydroperoxyl radical with alpha-phenyl-N-tert-butylnitrone (PBN) derivatives. J Phys Chem .<\/i>, 112<\/b>, 12498–12509 (2008)."},{"key":"43","unstructured":"43) Wang P, Zweier JL: Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol Che.<\/i>, 271<\/b>, 29223–29230 (1996)."},{"key":"44","unstructured":"44) Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P: Redox regulation of cell survival. Antioxid Redox Signa.<\/i>, 10<\/b>, 1343–1374 (2008)."},{"key":"45","unstructured":"45) Ebadi M, Srinivasan SK, Baxi MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobio.<\/i>, 48<\/b>, 1–19 (1996)."},{"key":"46","unstructured":"46) Jenner P, Olanow CW: Understanding cell death in Parkinson's disease. Ann Neuro.<\/i>, 44<\/b>, S72–84 (1998)."},{"key":"47","unstructured":"47) George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, Finkelstein DI: Targeting the progression of Parkinson's disease. Curr Neuropharmaco.<\/i>, 7<\/b>, 9–36 (2009)."},{"key":"48","unstructured":"48) Ganapathy PS, White RE, Ha Y, Bozard BR, McNeil PL, Caldwell RW, Kumar S, Black SM, Smith SB: The role of N-methyl-D-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest Ophthalmol Vis Sc.<\/i>, 52<\/b>, 5515–5524 (2011)."},{"key":"49","unstructured":"49) Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S: L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neuro.<\/i>, 67<\/b>, 600–606 (2010)."},{"key":"50","unstructured":"50) Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, Videnovic A, Weaver FM, Williams K, Surmeier DJ: Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disor.<\/i>, 25<\/b>, 2863–2866 (2010)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/2\/37_b13-00743\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:39:05Z","timestamp":1615873145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/2\/37_b13-00743\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b13-00743","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}